BridgeBio Pharma, Inc. BBIO
65.57
(0.71)
(1.07%)
as of 25 Sep
- Market cap
- $13.1B
- P/E
- 0.0×
Follow BBIO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 32.31% | 36.94% | 41.03% | 50.74% |
+8 more TTM periods Free account |
|
| (60.23%) | (64.06%) | (78.14%) | (95.85%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(333.08%) | (167.85%) | (140.72%) | (126.81%) | |
Average Days of Receivables |
130.26 | 129.16 | 101.37 | 120.21 | |
Free Cash Flow per Share |
(2.22) | (2.29) | (2.38) | (3.12) | |
Free Cash Flow |
(435.39) | (445.12) | (455.55) | (597.75) | |
Capital Expenditures |
(1.01) | (1.17) | (9.64) | (12.93) | |
Piotroski F-Score |
4.00 | 4.00 | 2.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(304.15%) | (74.20%) | (122.52%) | (101.85%) | |
Accounts Receivable Turnover |
4.30 | 3.62 | 6.97 | 6.05 | |
Accounts Payable Turnover |
1.49 | 1.00 | 0.91 | 0.93 | |
Inventory Turnover |
1.12 | 1.53 | 0.00 | 0.00 | |
Average Days of Payables |
250.38 | 375.28 | 630.82 | 456.94 | |
Days of Inventory on Hand |
486.38 | 425.93 | 465.84 | 599.26 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
70.87% | 80.55% | 90.02% | 131.69% | |
Selling, General and Administrative Expense of Revenue |
90.58% | 101.52% | 105.81% | 132.26% | |
Share Based Compensation of Revenue |
20.65% | 24.21% | 26.49% | 36.33% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.63 | 0.62 | 0.62 | 0.73 | |
Depreciation/Fixed assets |
2.24 | 2.33 | 2.12 | 2.20 | |
Capex/Depreciation |
(0.09) | (0.10) | (0.85) | (1.01) | |
Revenue per Share |
3.64 | 2.98 | 2.62 | 1.84 | |
Operating CF per Share |
(2.22) | (2.28) | (2.33) | (3.05) | |
Capex per Share |
(0.01) | (0.01) | (0.05) | (0.07) | |
Capex to Sales |
0.00 | 0.00 | 0.02 | 0.04 | |
Net Profit Margin |
(97.03%) | (124.41%) | (144.39%) | (225.31%) |
Columns are period end dates